The stock price of Summit Therapeutics Inc (NASDAQ: SMMT) has jumped by 2.48 compared to previous close of 24.61. Despite this, the company has seen a gain of 8.52% in its stock price over the last five trading days. seekingalpha.com reported 2025-04-14 that Summit Therapeutics’ ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition exists in the PD-1/VEGF bispecific antibody space, with major players like Merck and BioNTech entering the market. Summit’s financial health shows a significant cash runway into late 2027, despite high R&D and G&A expenses and no revenue generation.
Is It Worth Investing in Summit Therapeutics Inc (NASDAQ: SMMT) Right Now?
Moreover, the 36-month beta value for SMMT is -0.98. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SMMT is 111.14M and currently, short sellers hold a 21.38% of that float. On April 22, 2025, SMMT’s average trading volume was 2.94M shares.
SMMT’s Market Performance
The stock of Summit Therapeutics Inc (SMMT) has seen a 8.52% increase in the past week, with a 29.73% rise in the past month, and a 32.53% gain in the past quarter. The volatility ratio for the week is 10.58%, and the volatility levels for the past 30 days are at 10.30% for SMMT. The simple moving average for the past 20 days is 21.32% for SMMT’s stock, with a 39.40% simple moving average for the past 200 days.
Analysts’ Opinion of SMMT
Many brokerage firms have already submitted their reports for SMMT stocks, with Citigroup repeating the rating for SMMT by listing it as a “Buy.” The predicted price for SMMT in the upcoming period, according to Citigroup is $35 based on the research report published on March 26, 2025 of the current year 2025.
Evercore ISI gave a rating of “Outperform” to SMMT, setting the target price at $30 in the report published on March 12th of the current year.
SMMT Trading at 24.77% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.58% of loss for the given period.
Volatility was left at 10.30%, however, over the last 30 days, the volatility rate increased by 10.58%, as shares surge +27.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.01% upper at present.
During the last 5 trading sessions, SMMT rose by +8.52%, which changed the moving average for the period of 200-days by +234.48% in comparison to the 20-day moving average, which settled at $20.79. In addition, Summit Therapeutics Inc saw 41.33% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SMMT
The total capital return value is set at -0.54. Equity return is now at value -94.89, with -69.32 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -19.69. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -24.28.
Currently, EBITDA for the company is 0.31 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.15.
Conclusion
To wrap up, the performance of Summit Therapeutics Inc (SMMT) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
